| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 17, 2006
From the Children’s Hospital, Harvard Medical School, Boston, Mass (S.D.C., J.M., G.F.C.); Holtz Children’s Hospital, University of Miami, Miami, Fla (S.E.L.); New England Research Institutes, Watertown, Mass (A.M.L., L.A.S.); Genzyme Corporation, Cambridge, Mass (G.F.C.); Albany Medical College, Albany, NY (P.R.L.); Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (E.J.O.); and Texas Children’s Hospital, Baylor College of Medicine, Houston (J.A.T.). * To whom correspondence should be addressed. E-mail: colan{at}alum.mit.edu.
Background--Current information on the epidemiology and outcomes of hypertrophic cardiomyopathy (HCM) in children is limited by disease diversity and small case series. Methods and Results--The Pediatric Cardiomyopathy Registry has collected prospective and retrospective data on children diagnosed with HCM since 1990. We identified the various causes of HCM in childhood and determined the relationship between outcomes, cause, and age at presentation. Of 855 patients <18 years of age with HCM, 8.7% (n=74) had inborn errors of metabolism, 9.0% (n=77) had malformation syndromes, 7.5% (n=64) had neuromuscular disorders, and 74.2% (n=634) had idiopathic HCM. Children with HCM associated with inborn errors of metabolism and malformation syndromes have significantly worse survival than the other 2 groups. Patients with idiopathic HCM diagnosed before 1 year of age (n=227) had worse survival from the time of diagnosis than those diagnosed after 1 year of age (n=407). Patients with idiopathic HCM who survived to at least 1 year of age, however, had an annual mortality rate of 1% that was similar regardless of whether they were diagnosed before or after 1 year of age. Conclusions--In children, HCM is a diverse disorder with outcomes that depend largely on cause and age. Patients presenting before 1 year of age have the broadest spectrum of causes and the poorest outcome. In those children with idiopathic HCM who survive beyond age 1, however, survival is independent of age at diagnosis, with an annual mortality rate (1%) that is much lower than previously reported in children and is not different from has been found in population-based studies in adults.
Accepted on December 11, 2006
Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children. Findings From the Pediatric Cardiomyopathy Registry
Steven D. Colan MD*,
This article has been cited by other articles:
![]() |
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62. [Full Text] [PDF] |
||||
![]() |
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons Circulation, May 27, 2008; 117(21): e350 - e408. [Full Text] [PDF] |
||||
![]() |
I. Ostman-Smith, G. Wettrell, B. Keeton, D. Holmgren, U. Ergander, S. Gould, C. Bowker, and M. Verdicchio Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy Eur. Heart J., May 1, 2008; 29(9): 1160 - 1167. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Morita, H. L. Rehm, A. Menesses, B. McDonough, A. E. Roberts, R. Kucherlapati, J. A. Towbin, J.G. Seidman, and C. E. Seidman Shared Genetic Causes of Cardiac Hypertrophy in Children and Adults N. Engl. J. Med., May 1, 2008; 358(18): 1899 - 1908. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ganame, R. H. Pignatelli, B. W. Eidem, P. Claus, J. D'hooge, C. J. McMahon, G. Buyse, J. A. Towbin, N. A. Ayres, and L. Mertens Myocardial deformation abnormalities in paediatric hypertrophic cardiomyopathy: are all aetiologies identical? Eur J Echocardiogr, April 27, 2008; (2008) jen150v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Webber New-Onset Heart Failure in Children in the Absence of Structural Congenital Heart Disease Circulation, January 1, 2008; 117(1): 11 - 12. [Full Text] [PDF] |
||||
![]() |
T. P. Graham Jr The Year in Congenital Heart Disease J. Am. Coll. Cardiol., July 24, 2007; 50(4): 368 - 377. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |